source
- Alkermes reports early proof-of-concept for orexin-2 drug in ADHDAlkermes announced early-stage trial results for ALKS 7290, an orexin‑2 receptor agonist originally being developed for narcolepsy, showing proof of concept in ADHD. The study reported dose‑depend…
- US officials launch probe into falling German drug prices amid EU pharma push for competitivenessUS trade officials held a hearing on Tuesday about a possible investigation into the decline in Germany's payments for pharmaceuticals. Testimony presented arguments both supporting and opposing t…